California Resources Corporation (NYSE:CRC)

California Resources Corporation is engaged in exploration and production of oil and gas. The Company produces, gathers, processes and markets crude oil, natural gas, natural gas liquids and electricity primarily in the State of California. California Resources Corporation is based in Los Angeles, California.

California Resources Corporation (NYSE:CRC)’s Financial Overview

California Resources Corporation (NYSE:CRC) surged 44.4% yesterday to close its trading session at $17.4. The company has 1 year Price Target of $14.2. California Resources Corporation has 52-Week high of $39.5 and 52-Week Low of $2.81. The stock touched its 52-Week High on Dec 3, 2015 and 52-Week Low on Feb 25, 2016. The stock traded with the volume of 11.96 Million shares yesterday. The firm shows the market capitalization of $717.23 Million.

California Resources Corporation (NYSE:CRC) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-1.75/share against the analyst consensus estimate of $-1.55/share. The difference between the actual and expected EPS is $-0.2 a share with a surprise factor of -12.9%.

The firm is trading with SMA20 of 33.25 Percent, SMA50 of 43.91 Percent and SMA200 of 33.89 percent. California Resources Corporation has P/S value of 0.4 while its P/B value stands at 0. Similarly, the company has Return on Assets of -44.1 percent, Return on Equity of 343.6 percent and Return on Investment of -58.4 Percent. The company shows Gross Margin and Operating Margin of 55.2 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on California Resources Corporation (NYSE:CRC). On 22-Nov-16 Morgan Stanley Upgrade California Resources Corporation Stock  to Equal-Weight. Another firm also rated the stock on 2-Mar-16 where Societe Generale Downgrade the stock to Hold.

The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 6 analysts offering 12-month price forecasts for California Resources Corp have a median target of 11.00, with a high estimate of 20.00 and a low estimate of 7.00. The median estimate represents a -36.78% decrease from the last price of 17.40.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s Financial Outlook

The 7 analysts offering 12-month price forecasts for Celldex Therapeutics Inc have a median target of 7.00, with a high estimate of 12.00 and a low estimate of 3.00. The median estimate represents a +83.73% increase from the last price of 3.81.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Celldex Therapeutics, Inc. has a Consensus Recommendation of 2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -5.22% and closed its last trading session at $3.81. The company has the market capitalization of $385.8 Million. The stock has 52-week high of $18.01 and 52-Week low of $2.85. The firm touched its 52-Week high on Dec 3, 2015 and 52-Week low on Nov 3, 2016. The company has volume of 2.11 Million shares. The company has a total of 101.26 Million shares outstanding.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the last quarter reported its actual EPS of $-0.29/share where the analyst estimated EPS was $-0.33/share. The difference between the actual and Estimated EPS is $0.04. This shows a surprise factor of 12.1 percent.

The company has YTD performance of -75.7 percent. Beta for Celldex Therapeutics, Inc. stands at 3.24 while its ATR (average true range) is 0.3. The company has Weekly Volatility of 8.37%% and Monthly Volatility of 8.54%%.

Celldex Therapeutics, Inc. has distance from 20-day Simple Moving Average (SMA20) of -5.58%, Distance from 50-Day Simple Moving Average of -0.67 percent and Distance from 200-Day Simple Moving Average of -10.66%.

The Company currently has ROA (Return on Assets) of -44.3 percent, Return on Equity (ROE) of -51.5 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.